Scalper1 News
Axovant Sciences (AXON) on Thursday made the biggest biotech initial public offering in at least the past 20 years, raising $315 million. Axovant offered 21 million shares at 15, the high end of its estimated price range. The stock doubled to near 30 in its Thursday debut. That price gives Axovant, which is developing a drug for Alzheimer’s disease, a market valuation above $2.7 billion, staggering for a company with no revenue. Data on the Scalper1 News
Scalper1 News